| 44.5 -0.8 (-1.77%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 63.36  |
1-year : | 71.02 |
| Resists | First : | 54.25 |
Second : | 60.81 |
| Pivot price | 48.94 |
|||
| Supports | First : | 43.63 |
Second : | 36.3 |
| MAs | MA(5) : | 46.7 |
MA(20) : | 51.1 |
| MA(100) : | 54.64 |
MA(250) : | 42.76  |
|
| MACD | MACD : | -3.1 |
Signal : | -2.7 |
| %K %D | K(14,3) : | 10.4 |
D(3) : | 16.3 |
| RSI | RSI(14): 29.2 |
|||
| 52-week | High : | 66.54 | Low : | 20.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RXST ] has closed above bottom band by 18.7%. Bollinger Bands are 54.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 46.49 - 46.77 | 46.77 - 46.98 |
| Low: | 43 - 43.35 | 43.35 - 43.62 |
| Close: | 44.03 - 44.56 | 44.56 - 44.95 |
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Thu, 25 Jul 2024
RxSight, Inc. (NASDAQ:RXST) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Thu, 25 Jul 2024
Sei Investments Co. Reduces Stock Position in RxSight, Inc. (NASDAQ:RXST) - Defense World
Thu, 25 Jul 2024
RxSight, Inc. (NASDAQ:RXST) Given Average Recommendation of “Buy” by Brokerages - Defense World
Tue, 23 Jul 2024
RxSight price target raised to $68 from $61 at Wells Fargo - TipRanks
Tue, 23 Jul 2024
Swiss National Bank Boosts Stock Position in RxSight, Inc. (NASDAQ:RXST) - Defense World
Mon, 22 Jul 2024
RxSight, Inc. (NASDAQ:RXST) Shares Purchased by Hillsdale Investment Management Inc. - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 39 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 5.2 (%) |
| Held by Institutions | 85.2 (%) |
| Shares Short | 1,850 (K) |
| Shares Short P.Month | 1,450 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.4 |
| Profit Margin | -44.1 % |
| Operating Margin | -36.2 % |
| Return on Assets (ttm) | -15.5 % |
| Return on Equity (ttm) | -28.9 % |
| Qtrly Rev. Growth | 68.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.57 |
| EBITDA (p.s.) | -1.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -35.89 |
| PEG Ratio | -3.1 |
| Price to Book value | 10.09 |
| Price to Sales | 17.27 |
| Price to Cash Flow | -52.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|